
## Shamaila Munir Ahmad

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/84401/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment. Oncolmmunology, 2016, 5, e1238541.	4.6	56
2	Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNI <sup>3</sup> Signaling. Cancer Research, 2017, 77, 4562-4566.	0.9	39
3	PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine. Oncolmmunology, 2016, 5, e1202391.	4.6	33
4	The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy. Oncolmmunology, 2018, 7, e1390641.	4.6	33
5	Frequent adaptive immune responses against arginase-1. Oncolmmunology, 2018, 7, e1404215.	4.6	27
6	Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer. Oncolmmunology, 2015, 4, e968480.	4.6	25
7	<i>Staphylococcus aureus</i> alpha-toxin inhibits CD8 <sup>+</sup> T cell-mediated killing of cancer cells in cutaneous T-cell lymphoma. OncoImmunology, 2020, 9, 1751561.	4.6	24
8	PD-L1-specific T cells. Cancer Immunology, Immunotherapy, 2016, 65, 797-804.	4.2	20
9	Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial. Frontiers in Immunology, 2020, 11, 595035.	4.8	17
10	Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial. Stem Cell Investigation, 2016, 3, 95-95.	3.0	16
11	Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope. Cancer Immunology, Immunotherapy, 2019, 68, 1901-1907.	4.2	16
12	Peripheral memory T cells specific for Arginase-1. Cellular and Molecular Immunology, 2019, 16, 718-719.	10.5	13
13	Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment. Oncolmmunology, 2022, 11, 2026020.	4.6	9
14	Spontaneous presence of FOXO3-specific T cells in cancer patients. Oncolmmunology, 2014, 3, e953411.	4.6	4